Atomic layer coating to inhibit surface crystallization of amorphous pharmaceutical powders

DE Moseson, EG Benson, HT Nguyen… - … Applied Materials & …, 2022 - ACS Publications
Preventing crystallization is a primary concern when developing amorphous drug
formulations. Recently, atomic layer coatings (ALCs) of aluminum oxide demonstrated …
被引用次数：9 相关文章

Atomic Layer Coating to Inhibit Surface Crystallization of Amorphous Pharmaceutical Powders.

DE Moseson, EG Benson, HT Nguyen… - … Applied Materials & …, 2022 - europepmc.org
Preventing crystallization is a primary concern when developing amorphous drug
formulations. Recently, atomic layer coatings (ALCs) of aluminum oxide demonstrated …

Atomic Layer Coating to Inhibit Surface Crystallization of Amorphous Pharmaceutical Powders

DE Moseson, EG Benson, HT Nguyen, F Wang… - pharmaexcipients.com
EH60 (no coating) 44.6 EH60 (Al2O3 13 nm) 43.9 EH60 (Al2O3 14 nm) 44.0 EP50 (no
coating) 44.6 EP50 (Al2O3 7.4 nm) 44.2 EP50 (Al2O3 14 nm) 44.1 NH10 (no coating) 78.1 …

Atomic Layer Coating to Inhibit Surface Crystallization of Amorphous Pharmaceutical Powders

DE Moseson, EG Benson… - … applied materials & …, 2022 - pubmed.ncbi.nlm.nih.gov
Preventing crystallization is a primary concern when developing amorphous drug
formulations. Recently, atomic layer coatings (ALCs) of aluminum oxide demonstrated …

[引用][C] Atomic Layer Coating to Inhibit Surface Crystallization of Amorphous Pharmaceutical Powders

DE Moseson, EG Benson, HT Nguyen, F Wang… - 2022